Fatigue in Lupus Intervention Programmes (FLIP)

More detail

The FLIP study will recruit SLE patients to a single centre, three arm randomised controlled trial which will compare standard care ( fatigue booklets available in all Rheumatology departments in the UK or online ) with live online fatigue management groups for effectiveness at managing fatigue. Lupus UK will advertise the study through their website, newsletter and social media. Participants can be identified and enrolled to the study in three ways: 1. The participant can be identified by any member of the Rheumatology department in NHS Lothian through participant routine Rheumatology appointment or local database. No patient records will be screened . 2. Participants can be identified through the Scottish Lupus Registry Database as they will have already consented to being contacted about research. 3. Participants can also self-enrol to the study through the link to the FLIP website from Lupus UK . Posters, leaflets and LUPUS UK communications will have a link and QR code which will take interested participants to the patient information sheet to read about the study.They can contact the study team with any questions before proceeding to accessing the enrolment process in the REDCap secure server. The central study team or the participant themselves can confirm their eligibility by completing short screening questions.The study team can also help the patient with any questions regarding the online consent form if necessary. If the participant is eligible and wishes to proceed they will be asked to complete an online consent and be assigned a unique identification code number (UICN). After the participant has consented online in REDCap and completed personal details/demographics and baseline PROMs questionnaires they will be randomised to either standard care, standard care plus 4 week programme or standard care plus 7 week programme. The ratio of randomisation will be 1.1.1 . Participants will complete the same PROMS three more times after the baseline: on completion of the intervention, at 6 months and at 12 months. The PROMs will be 1. Modified Fatigue Impact Score (MFIS) 2. SLE quality of life questionnaire (LupusQoL) 3. Pittsburgh Sleep quality Inventory ( PSQI) 4. Visual Analog scale of fatigue impact ( FI-VAS) 5. Participant health questionnaire -4 item (PHQ4) 6. Self -Efficacy for managing chronic disease 6 item scale (SEMCD-6) 7. Quick Systemic Lupus Activity Questionnaire (Q-SLAQ) If a participant has access to a Systemic Lupus Erythematosus Disease Activity Index ( SLEDAI) score this may be included . Participants will also be asked to complete a satisfaction questionnaire after the intervention completion. The end of study is defined as the last data collection at 52 weeks from the last participant after group intervention or standard care whichever comes last. The trial team will analyse the qualitative data from participants. A health economist will calculate the NHS utilisation / economic evaluation by mapping the LUPUSQoL to the Short Form 6 dimension (SF6D) to obtain quality adjusted life years (QALYs) . A statistician will analyse the data from the PROMs with standard statistical software in R and report descriptive statistics such as means, medians, standard deviations and standard errors of the variables measured. Statistical significance will be measured for the aims of the study using unmatched and paired T- tests. The primary outcome of our study, MFIS measurements, will be assessed using linear regression models including a random effect to account for grouping by centre. The investigators will assess whether the treatment outcome is maintained by analysing longitudinal data collected over 1 year using linear mixed-effect models with a suitable covariance structure. The secondary outcomes will be analysed in an analogous way. The investigators will also analyse how the secondary outcomes covary with the MFIS scores. The investigators will handle non-compliance by analysing the data according to intention-to-treat principles. In the unlikely event of unused data arising, the investigators will include these in suitable subgroup analyses. Spurious data will be followed up with patients and will only be excluded from the study as a measure of last resort. The investigators are not planning to carry out interim analyses nor to terminate the study early. The results will be published in peer reviewed journals and by Lupus UK .